Skip to main content
Premium Trial:

Request an Annual Quote

Counsyl, Angsana to Commercialize Expanded Carrier Screening in Hong Kong

NEW YORK (GenomeWeb) – Counsyl and Angsana Molecular & Diagnostics Laboratory plan to commercialize Counsyl's expanded carrier screening test in Hong Kong.

Under an agreement, molecular diagnostic firm Angsana will be able to make Counsyl's test available to its network of physicians in Hong Kong.

Financial and other terms of the deal were not disclosed.

Counsyl's expanded carrier screening test uses next-generation sequencing to identify carriers for over 100 inherited disorders. Samples will be processed at Counsyl's CLIA-certified laboratory in South San Francisco, California.

Angsana is headquartered in Singapore, but has offices in Hong Kong and Malaysia. It develops molecular diagnostic assays relevant for the Asian population in the areas of allergy, fetal maternal health, oncology, and pharmacogenetics.

"This expansion is part of our larger strategic effort to increase global access to comprehensive, clinically relevant, and affordable testing in women's health," Counsyl Senior Vice President of Corporate Development Matthew Meyer said in a statement.

Angsana Founder and CEO Chris Tan added that the firm wants to offer Counsyl's panel because of "its coverage of serious, clinically actionable and prevalent diseases, which is aligned to our mission of empowering doctors and patients in making better informed decisions."